Joint (JYNT) AI Stock Analysis

• Market Cap: $132.76M
• Dividend Yield: N/A
• Average Volume (3M): 133.50K
• Price to Earnings (P/E): 70.5
• Beta (1Y): 1.02
• Revenue Growth: -54.93%
• EPS Growth: N/A
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 14,866,192
• 10 Day Avg. Volume: 118,391
• 30 Day Avg. Volume: 133,496
• PEG Ratio: 1.36
• Price to Book (P/B): 8.85
• Price to Sales (P/S): 3.06
• P/FCF Ratio: 19.27
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 81.93
• Enterprise Value/Gross Profit: -11.70
• Enterprise Value/Ebitda: -82.55
• 1Y Price Target: $11.33
• Price Target Upside: 27.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.04
• Revenue Forecast (FY): $54.01M

• Rating: 54 Neutral
• Price Target: $9.00 ▲(0.90% Upside)

Joint's overall stock score reflects significant challenges in financial performance, with consistent net losses and declining revenue. While technical indicators show some short-term momentum, the high P/E ratio suggests overvaluation. The earnings call provided a mixed outlook, with growth in revenue and strategic initiatives offset by declining sales metrics and economic headwinds.

Positive Factors

Revenue and EBITDA Growth

The growth in revenue and EBITDA indicates effective strategic initiatives and operational improvements, enhancing long-term profitability.

Refranchising Strategy

Refranchising corporate clinics can streamline operations and improve financial health by reducing overhead and focusing on core competencies.

Digital Marketing Initiatives

Enhanced digital marketing and SEO improvements increase brand visibility and customer acquisition, supporting long-term growth.

Negative Factors

Decline in Sales Metrics

Declining sales metrics indicate potential challenges in market demand or competitive positioning, impacting future revenue growth.

Revised Guidance and Economic Headwinds

Revised guidance reflects challenges in adapting to economic conditions, potentially affecting financial performance and strategic planning.

Cash Flow Sustainability

Inconsistent cash flow generation can hinder the company's ability to invest in growth opportunities and maintain financial stability.

Joint Business Overview & Revenue Model

Company Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

How the Company Makes Money

Joint generates revenue through the sale of its dietary supplements and joint health products, which are distributed via various channels including e-commerce platforms, retail partnerships, and direct-to-consumer sales. The company has established key partnerships with health and wellness retailers, enabling broader market access and visibility for its products. Additionally, Joint may engage in subscription models for ongoing customer purchases, providing a steady revenue stream. The company's marketing strategies, including influencer partnerships and targeted advertising, contribute to customer acquisition and brand loyalty, further enhancing its earnings potential.

Joint Financial Statement Overview

Summary

Joint faces challenges with profitability and cash flow sustainability despite maintaining reasonable margins and low leverage. The decline in revenue and equity over recent periods highlights potential financial instability, and consistent net losses are a significant concern for future growth.

Income Statement

The company has seen fluctuating revenue with a notable decline from 2023 to TTM (Trailing-Twelve-Months). Gross profit margin remains strong at approximately 63.5% for TTM. However, the consistent negative EBIT and net loss indicate ongoing operational challenges and profitability issues, as evidenced by negative net profit margins.

Balance Sheet

The balance sheet shows reasonable stability with a debt-to-equity ratio of about 0.11 in TTM, indicating low leverage. However, the decline in equity over the years and the low return on equity due to negative net income suggest potential financial stress. The equity ratio stands at 25.8%, showing moderate reliance on equity financing.

Cash Flow

Cash flow analysis shows positive operating cash flow, but decreasing over the periods. Free cash flow is positive but has been inconsistent, reflecting challenges in maintaining cash generation. The operating cash flow to net income ratio is negative due to consistent net losses, highlighting potential cash flow sustainability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44M	52.16M	46.98M	101.25M	80.01M	58.68M
Gross Profit	-10.11M	40.65M	36.50M	92.08M	72.35M	52.18M
EBITDA	-1.43M	2.90M	8.88M	7.89M	10.07M	8.18M
Net Income	-799.12K	-5.80M	-9.75M	626.71K	7.57M	13.17M
Balance Sheet
Total Assets	69.39M	83.15M	87.21M	93.49M	87.06M	65.88M
Cash, Cash Equivalents and Short-Term Investments	30.71M	25.05M	18.15M	9.75M	19.53M	20.55M
Total Debt	2.09M	795.03K	2.86M	26.06M	23.62M	18.48M
Total Liabilities	46.66M	62.48M	62.44M	60.90M	56.75M	44.75M
Stockholders Equity	22.70M	20.65M	24.75M	32.56M	30.28M	21.13M
Cash Flow
Free Cash Flow	1.63M	8.23M	9.68M	2.31M	6.85M	8.03M
Operating Cash Flow	3.07M	9.42M	14.68M	8.21M	13.84M	11.18M
Investing Cash Flow	6.52M	-631.55K	-6.19M	-17.90M	-12.75M	-4.60M
Financing Cash Flow	-873.09K	-2.00M	174.12K	328.61K	-2.00M	5.60M

Joint Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.92
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JYNT, the sentiment is Positive. The current price of 8.92 is above the 20-day moving average (MA) of 8.54, above the 50-day MA of 8.36, and below the 200-day MA of 10.23, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 60.66 is Neutral, neither overbought nor oversold. The STOCH value of 72.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JYNT.

Joint Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	74 Outperform	$2.16B	21.43	9.94%	1.78%	23.74%	-18.99%
USPH	63 Neutral	$1.19B	33.02	7.30%	2.29%	17.50%	154.28%
ASTH	56 Neutral	$1.12B	119.16	1.29%	―	68.17%	-85.42%
JYNT	54 Neutral	$132.76M	70.51	-1.37%	―	-54.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TOI	47 Neutral	$377.78M	-5.38	-3407.86%	―	21.67%	16.74%
MODVQ	42 Neutral	$143.54K	>-0.01	―	―	-0.70%	-2.38%

Joint Corporate Events

Joint Corp. Terminates Southern California Clinics Sale

On December 5, 2025, The Joint Corp. entered into an Asset Purchase Agreement to sell 22 company-owned or managed clinics in Virginia, North Carolina, and South Carolina to a group of buyers for approximately $1.5 million. The transaction, which involves existing franchise community members, is expected to enhance the company’s strategic initiatives and growth. Additionally, on December 11, 2025, The Joint Corp. terminated a previous agreement to sell 45 clinics in Southern California due to the buyer’s failure to meet closing conditions, with no penalties incurred.

Joint Corp. Sells Clinics in $4.5M Deal

On November 2, 2025, The Joint Corp. entered into an Asset Purchase Agreement with Elite Chiro Group to sell the assets of 45 clinics in Southern California for $4.5 million. This transaction includes franchise rights and is subject to certain conditions, including lease assignments and customary closing conditions. Additionally, The Joint Corp. has been authorized to repurchase an additional $12 million of its stock, reflecting confidence in its growth and profitability strategies. The company reported a 6% revenue increase in Q3 2025 compared to Q3 2024, with significant improvements in net income and adjusted EBITDA, despite a slight decline in system-wide sales.

Joint Amends Credit Agreement with JPMorgan Chase

On September 30, 2025, Joint company entered into a consent and third amendment to its existing credit agreement with JPMorgan Chase Bank. This amendment includes the lender’s consent to the refranchising of all company-owned or managed clinics and extends the revolving credit maturity date to August 31, 2027, potentially impacting the company’s operational flexibility and financial strategy.